Key Takeaways
- • Amulet Capital Partners, a US-based healthcare-focused private equity firm headquartered in Greenwich, Connecticut and Walnut Creek, California, has acquired TFP Fertility Group from Benefit Street Partners (a Franklin Templeton company) in an all-cash transaction with undisclosed financial terms announced May 2026.
- • TFP Fertility operates an integrated network of 10 fertility clinics and 21 satellite/referral centres across the UK and Poland, positioning it as a leading fertility care provider in the UK and Northern Europe with established clinical credentials and scientific leadership.
- • Existing management continuity guaranteed: CEO Jude Fleming and the current management team will remain in place; clinical leadership and standards of care will remain unchanged, with TFP continuing to operate under its existing brand identity.
- • Amulet's investment strategy focuses on expanding patient access, enhancing clinical experience, and scaling TFP's market position across the UK and Northern Europe through leveraging Amulet's healthcare sector expertise and track record in building fertility provider businesses.
- • This acquisition reflects Amulet's thesis on healthcare consolidation and patient-centred care delivery, with the firm committing long-term capital to support growth initiatives while maintaining TFP's values-driven clinical ethos.
Summary
Amulet Capital Partners has completed its acquisition of TFP Fertility Group, one of the leading fertility care providers operating across the United Kingdom and Northern Europe, from Benefit Street Partners, a Franklin Templeton company. The transaction was announced in May 2026, though financial terms remain undisclosed. The deal represents a significant ownership transition for TFP, which has operated an established network of fertility clinics and referral centres since inception.
TFP Fertility's operational footprint comprises 10 primary fertility clinics supported by 21 satellite and referral centres distributed across the UK and Poland. The company has built a reputation for high clinical standards, patient-centred care delivery, and scientific leadership within the fertility services sector. This operational scale and geographic presence position TFP as a material player in the UK and Northern European fertility care markets, which have experienced consolidation activity over recent years.
Amulet Capital Partners is a middle-market private equity investment firm exclusively focused on healthcare sector investments, with offices in Greenwich, Connecticut and Walnut Creek, California. The firm brings extensive experience in building and scaling healthcare services businesses, including prior fertility provider investments. Amulet's acquisition of TFP reflects the firm's strategic thesis on supporting high-quality, patient-centred healthcare providers with long-term growth capital and operational expertise. According to Amulet's statement, the partnership marks "the beginning of a new phase of investment and momentum" enabling TFP to drive continued growth while maintaining clinical excellence.
Jude Fleming will continue as Group Chief Executive Officer, with the existing management team and clinical leadership structure remaining intact. This management continuity underscores Amulet's intention to preserve TFP's operational and cultural identity while providing financial resources and strategic support for expansion. Fleming stated that Amulet's "deep experience in healthcare and long-term perspective" aligns closely with TFP's values and clinical ethos, signalling strong sponsor-management alignment on strategy and operational priorities.
Going forward, Amulet and TFP plan to focus on expanding patient access to fertility services, enhancing the patient experience across the clinic network, and strengthening TFP's competitive positioning in core markets. The transaction was advised by McDermott Will & Schulte (representing Amulet) and Mills & Reeve (representing the seller).
TFP Fertility's operational footprint comprises 10 primary fertility clinics supported by 21 satellite and referral centres distributed across the UK and Poland. The company has built a reputation for high clinical standards, patient-centred care delivery, and scientific leadership within the fertility services sector. This operational scale and geographic presence position TFP as a material player in the UK and Northern European fertility care markets, which have experienced consolidation activity over recent years.
Amulet Capital Partners is a middle-market private equity investment firm exclusively focused on healthcare sector investments, with offices in Greenwich, Connecticut and Walnut Creek, California. The firm brings extensive experience in building and scaling healthcare services businesses, including prior fertility provider investments. Amulet's acquisition of TFP reflects the firm's strategic thesis on supporting high-quality, patient-centred healthcare providers with long-term growth capital and operational expertise. According to Amulet's statement, the partnership marks "the beginning of a new phase of investment and momentum" enabling TFP to drive continued growth while maintaining clinical excellence.
Jude Fleming will continue as Group Chief Executive Officer, with the existing management team and clinical leadership structure remaining intact. This management continuity underscores Amulet's intention to preserve TFP's operational and cultural identity while providing financial resources and strategic support for expansion. Fleming stated that Amulet's "deep experience in healthcare and long-term perspective" aligns closely with TFP's values and clinical ethos, signalling strong sponsor-management alignment on strategy and operational priorities.
Going forward, Amulet and TFP plan to focus on expanding patient access to fertility services, enhancing the patient experience across the clinic network, and strengthening TFP's competitive positioning in core markets. The transaction was advised by McDermott Will & Schulte (representing Amulet) and Mills & Reeve (representing the seller).
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.